The oral drug muvalaplin saw positive results in the first phase 1 study involving health participants for lipoprotein, a genetic marker for cardiovascular disease that's known for "sticky" cholesterol.
Muvalaplin, a drug under development at Eli Lilly, lowered lipoprotein levels by 65 percent, according to results published Aug. 28 in JAMA.
The medication could be the first treatment for lipoprotein, a genetic marker of cholesterol that increases the risk of heart attack and stroke. Lipoprotein is stickier than LDL cholesterol, and drugs indicated for LDL aren't as effective for lipoprotein, meaning muvalaplin has potential to be the first drug to tackle "sticky" cholesterol.